Literature DB >> 1377289

False positive prostate specific antigen values in the sera of women with renal cell carcinoma.

K Pummer1, G Wirnsberger, P Pürstner, H Stettner, G Wandschneider.   

Abstract

The assessment of serum prostate specific antigen (PSA) with a polyclonal radioimmunoassay in 22 women with renal cell carcinoma resulted in measurable values in 6 patients, with the values ranging from 0.5 to 27.0 ng./ml. Tumor stage was T3 in all of these patients and the morphological features showed an eosinophilic subtype according to the German nomenclature. Additional measurements with a monoclonal radioimmunoassay in 3 of these 6 patients were negative as were all subsequent measurements postoperatively, although performed with the polyclonal radioimmunoassay. Immunohistochemical staining was negative for PSA. However, positivity for alpha-1-antichymotrypsin was detected, which was reported to occur in complexes with PSA and other proteases. Cross reaction between the polyclonal antibodies of the radioimmunoassay and 1 of these complexes is concluded. As far as clinical considerations are concerned, such cross reaction must be considered just as likely in male patients. Thus, it is recommended that therapeutic considerations in patients who underwent radical prostatectomy, for example, should not be exclusively based on PSA measurement performed with a polyclonal assay.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377289     DOI: 10.1016/s0022-5347(17)36497-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Raised prostate-specific antigen in adenocarcinoma of the colon.

Authors:  M Yamamoto; H Hibi; K Miyake
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

3.  Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.

Authors:  B Bindukumar; Stanley A Schwartz; Madhavan P N Nair; Ravikumar Aalinkeel; Elzbieta Kawinski; Kailash C Chadha
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

4.  Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.

Authors:  H Yu; M A Levesque; G M Clark; E P Diamandis
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  A Case of Advanced Submandibular Gland Cancer in Which Increased Prostate-Specific Antigen and Multiple Bone Metastases Wrongly Suggested Concurrent Prostate Cancer.

Authors:  Yoko Fukasawa; Takeshi Honda; Maika Natsume; Terunobu Haruyama; Masashi Ishihara; Takahiko Sakamoto; Ryo Usui; Shigeru Tanzawa; Shuji Ota; Yasuko Ichikawa; Kiyotaka Watanabe; Koji Saito; Nobuhiko Seki
Journal:  Case Rep Oncol       Date:  2017-12-20

6.  Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.

Authors:  R E Hall; J A Clements; S N Birrell; W D Tilley
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.